1. Introduction {#s0005}
===============

Although multiple sclerosis (MS) affects the entire brain, lesions are more extensive and extra-lesional pathology more intense in the white matter (WM) and grey matter (GM) adjacent to the outer (i.e. subpial) and inner (i.e. ventricular) surfaces of the brain ([@bb0020], [@bb0045]).

Cortical lesions, for example, are frequently found near the subpial brain surface and are reported to be present in \> 80% of subjects with primary progressive MS (PPMS) ([@bb0030]). In all MS subtypes, the presence of subpial cortical lesions has been linked with meningeal inflammation, hinting a role for soluble inflammatory factors in modulating the spatial distribution of tissue damage. Moreover, while a periventricular predilection for lesion formation has been recognised for some time, ([@bb0005]) it has recently been shown in subjects with relapse-onset MS that extra-lesional WM abnormalities are also greater with proximity to the ventricles, even if the pathological bases of the latter observation are presently unknown ([@bb0015], [@bb0040], [@bb0045]).

Previous studies in subjects with relapse-onset MS have shown that periventricular WM lesions are associated with the extent of cortical atrophy ([@bb0035]) and that a declining gradient of damage severity from the brain surface inwards is present both in deep and in cortical GM, ([@bb0045]) thus suggesting that a common factor is involved in modulating cortical and periventricular pathology. Conversely, the association between tissue damage in these different tissue compartments in PPMS remains not characterized.

Here, given the wealth of information regarding cortical lesions pathophysiology ([@bb0025], [@bb0030], [@bb0055]), we sought to explore the association, if any, between cortical lesions and periventricular normal appearing (NA) WM abnormalities as measured by (i) diffusion tensor imaging and (ii) periventricular WM lesion volume in subjects with PPMS. Moreover, to better characterise the relationship between cortical pathology and structural damage, we also computed thickness of the cortical mantle.

2. Methods {#s0010}
==========

2.1. Subject selection {#s0015}
----------------------

Twenty-four subjects who met the modified McDonald diagnostic criteria and were running a PPMS course were prospectively enrolled as described elsewhere ([@bb0050]). Twenty sex- and age-matched healthy subjects served as controls. Inclusion criteria for PPMS patients were (i) age between 25 and 65 years, (ii) an Expanded Disability Status Scale (EDSS) equal or lower than 6.5 at screening visit, and (iii) disease duration lower than 15 years. The use of immuno-modulatory drugs was allowed but, if treated, patients had to be on current treatment for at least 1 year. In the US it is not uncommon for patients with PPMS to be tried on one of the approved immunomodulatory treatments despite the lack of Phase III clinical trials evidence. Therefore, although our sample is not universally representative, it is representative of the US practice. Exclusion criteria were (i) neuropsychiatric disorders other than MS, (ii) history of alcohol or drug abuse, and (iii) contraindications to MRI. Clinical and demographical information are reported in [Table 1](#t0005){ref-type="table"}.Table 1Clinical, demographic and conventional MRI data for the primary progressive multiple sclerosis (PPMS) and healthy controls (HC) groups.Table 1.PPMSHCAge (range, years)50.8 (32--65)51.1 (34--63)Gender (M/F)12/129/11Disease duration (years)9 ± 4.8--Median EDSS (range)4 (1.5--6)--Normalized brain volume (mL)1368.5 ± 59.11434.1 ± 53.6Normalized grey matter volume (mL)721.8 ± 37.5757.3 ± 39.0White matter T2 lesion volume (mL)5.9 ± 7.7--

2.2. MRI acquisition {#s0020}
--------------------

MRI was performed using a 3.0 T scanner (Philips Achieva, The Netherlands) with an 8-channel SENSE phased-array head coil (Philips Achieva, The Netherlands) as previously described ([@bb0050]). The MRI protocol included the following sequences: (i) axial dual echo/turbo spin echo sequence: repetition time (TR) = 2500 ms, echo time (TE1) = 10 ms, TE2 = 80 ms, field of view, FoV) = 230 mm × 230 mm, matrix size = 512 × 512, 46 contiguous 3-mm-thick slices; (ii) sagittal 3D T1-weighted turbo field echo sequence: TR/TE = 7.5/3.5 ms, inversion time (TI) = 900 ms, flip angle = 8°,voxel-size = 1 × 1 × 1 mm^3^, 172 contiguous slices; (iii) axial double inversion recovery (DIR) sequence: TR/TE = 11,000/25 ms, TI = 3400 ms; (iv) phase-sensitive inversion recovery (PSIR) sequence: TR/TE/TI = 4500/8/400 ms and (v) single-shot EPI for diffusion weighted imaging: TR/TE = 8550/89.5 ms b-values: 0,1000,2000 s/mm^2^ 32 non-collinear directions; voxel size 2 × 2 × 2 mm^3^. Both DIR and PSIR were acquired with 46 contiguous 3-mm-thick slices with in-plane reconstructed resolution of 0.5 mm × 0.5 mm.

2.3. MRI analysis {#s0025}
-----------------

Cortical lesions were identified according to published criteria, on PSIR images using DIR and T1 images as reference ([@bb0055]). A single observer blinded to clinical information and subject\'s identity, under the supervision of a senior investigator performed all the lesion loads. Intracortical (IC) lesions were defined as lesions that were confined to the cortex, while lesions that involved both cortex and juxtacortical white matter (WM) were identified as leucocortical lesions (LC). Juxtacortical lesions (JC) were differentiated from LC lesions based on preservation of normal cortical contour and absence of cortical involvement. Particular care was paid to exclude cortical vessels, Virchow Robin spaces and artefacts. JC lesions, involving only WM, were not included in further analysis, while LC and IC lesion volumes were summed to quantify total cortical lesion volume. WM lesions were identified on PD/T2 sequences and were then co-registered to diffusion data using a linear transformation. All lesions were marked using Jim version 6 (Xinapse Systems, Northants, England), using a semi-automated edge-finding tool based on local thresholding technique. FDT, included in the FSL toolbox, was used to perform eddy-current correction on diffusion data and to fit the diffusion tensor ([@bb0065]). Mean diffusivity (MD) NAWM maps were created excluding WM lesions and a 2 mm-thick peri-lesional rim as previously described ([@bb0040]). Mean diffusivity (MD) NAWM maps were created excluding WM lesions ). Skeletonized NAWM MD maps, normalized to a common space, were then computed using the TBSS pipeline ([@bb0070]). In each skeletonized NAWM MD map, those supra-tentorial voxels with a distance from the lateral ventricles between 2 and 6 mm were included in the periventricular NAWM mask while those voxels of skeletonized WM with a distance from the lateral ventricles between 6 and 10 mm were included in the deep NAWM mask. Thus all NAWM voxels with a distance from the ventricles \> 10 mm were not included neither in the periventricular NAWM mask nor in the deep NAWM mask ([Fig. 1](#f0005){ref-type="fig"}). For these two regions, both mean MD and percentage of lesioned WM were computed. Moreover, whole brain normalized grey matter (nGMV) volume and normalized brain volume (nBV), were computed using Sienax ([@bb0060]) on lesion-filled volumetric T1 images.Fig. 1Periventricular (represented in light grey) and deep (represented in dark grey) WM masks.Fig. 1.

Lastly, cortical thickness was measured with the Freesurfer (version v5.3.0) pipeline using lesion-filled volumetric T1 images. After Freesurfer analysis, all images were reviewed by two experienced operators.

2.4. Confirmatory analysis: FA data {#s0030}
-----------------------------------

Using the same pipeline described above, we also computed mean FA both in the skeletonized periventricular NAWM mask and the skeletonized periventricular NAWM mask. To take into account the regional differences in WM architecture, which could impact on FA values, we used control data to convert raw FA values to z scores using the following formula (FA_patient -- mean_FA_control_group)/standard_deviation_FA_control_group.

2.5. Confirmatory analysis: Deep NAWM parcellation from the cortical ribbon inward {#s0035}
----------------------------------------------------------------------------------

Lastly, we decided to confirm our findings using an alternative approach to create the deep NAWM mask, to try to accommodate for the convoluted architecture of the cortex. Firstly, we computed the distance from the cortical grey matter of all supratentorial voxels not previously included in the periventricular mask, and then included in the deep NAWM mask those voxels included in the farthest 4 mm from the cortex (in line with the previous parcellation in 4 mm-wide regions).

2.6. Statistical analysis {#s0040}
-------------------------

Independent-samples *t*-tests and paired-sample *t*-tests were used to compare NAWM MD values between PPMS subjects and controls and, in the PPMS group, between periventricular and deep NAWM.

Associations between cortical lesion load and tissue abnormalities were assessed with Pearson\'s correlations. Three subjects, for whom no cortical lesions were reliably identified, were excluded from the main correlation analyses only, however their inclusion in confirmatory analyses did not lead to significant changes in the results. Confirmatory analyses correcting for whole brain WM lesion load, nBV and nGMV were also performed using a partial correlations approach. Statistical significance was set at p \< 0.05, uncorrected. However for all non-confirmatory analyses, we also computed pFDR-corrected values based on the Benjamini--Hochberg methods. Statistical analysis was run with SPSS software version 20.0 (SPSS Inc., Chicago, IL, USA).

2.7. Ethics {#s0045}
-----------

Written informed consent was obtained from all participants according to the Declaration of Helsinki. The protocol was approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai.

3. Results {#s0050}
==========

3.1. Evaluation of periventricular NAWM abnormalities {#s0055}
-----------------------------------------------------

Compared to controls, PPMS subjects had higher MD values in periventricular (0.75 ± 0.06 mm^3^ / 10^− 3^ vs 0.83 ± 0.09 mm^3^ / 10^− 3^, p = 0.01, pFDR (corrected multiple comparisons) = 0.03) and deep NAWM regions (0.73 ± 0.05 mm^3^ / 10^− 3^ vs 0.77 ± 0.06 mm^3^ / 10^− 3^, p = 0.01, pFDR (corrected multiple comparisons) = 0.03)). Moreover, in the PPMS group, MD values were significantly higher in periventricular than deep NAWM (*t* = 3.43, p = 0.002, pFDR (corrected multiple comparisons) = 0.01)).

3.2. Association between periventricular abnormalities and cortical lesion volume {#s0060}
---------------------------------------------------------------------------------

A significant, direct correlation was observed between periventricular NAWM MD values and cortical lesion volume in the PPMS group (r = 0.65 p = 0.001, pFDR (corrected multiple comparisons) \< 0.01); [Fig. 2](#f0010){ref-type="fig"}-A), conversely there was no association between periventricular WM lesion load (percentage of lesioned WM: 5.3% ± 5.9) and cortical lesion volume (r = − 0.18, p = 0.43). Correction with whole brain WM lesion load, nBV or nGMV did not significantly alter the results.Fig. 2Correlations between cortical lesion load and periventricular NAWM MD values (**panel A**), and deep NAWM MD values (**panel B**). All data refer to primary progressive multiple sclerosis (PPMS) subjects. PPMS subjects (n = 3) without clearly evident cortical lesions were not included in these graphs.Fig. 2.

3.3. Association between deep white matter abnormalities and cortical lesion volume {#s0065}
-----------------------------------------------------------------------------------

There was no association between deep NAWM MD values and cortical lesion volume in the PPMS group (r = 0.14, p = 0.54, [Fig. 2](#f0010){ref-type="fig"}-B), nor between deep WM lesion load and cortical lesion volume (r = − 0.11, p = 0.59).

3.4. Association between periventricular and deep WM measures and cortical thickness {#s0070}
------------------------------------------------------------------------------------

There was no association between cortical thickness (mean thickness 2,5 ± 0,3 mm) and periventricular or deep NAWM MD values in the PPMS group (r = − 0.17, p = 0.473, r = − 0.04, p = 0.875). Cortical thickness did not correlate with periventricular and deep WM lesion load (r = − 0.20, p = 0.320, r = − 0.18, p = 0.379), or with whole brain WM lesion load (r = − 0.19, p = 0.363). Whole brain WM lesion load correlated with cortical lesions (r = 0.52, p = 0.02, pFDR (corrected multiple comparisons) = 0.06)), this correlation, however, did not survive an FDR-correction for multiple comparison.

3.5. Confirmatory analysis: FA {#s0075}
------------------------------

[I]{.ul}n the PPMS group z-scores converted FA data were significantly lower in the periventricular than deep NAWM (− 0.97 ± 0.3 vs. -0.79 ± 0.4, p = 0.003). The correlation between z-converted FA values and cortical lesion load was significant taking into account periventricular NAWM (r = − 0.56 p = 0.003), but not deep NAWM (p = 0.43).

3.6. Confirmatory analysis: Deep NAWM parcellation from the cortical ribbon inward {#s0080}
----------------------------------------------------------------------------------

Using the confirmatory parcellation of deep NAWM, there was no association between deep NAWM MD values and cortical lesion volume (r = 0.16, p = 0.50), nor between deep WM lesion load and cortical lesion volume (r = − 0.14, p = 0.48).

4. Discussion {#s0085}
=============

In this work, we showed that cortical lesions load was positively associated with periventricular NAWM abnormalities, but not with deep NAWM alterations nor with periventricular WM lesion load. These findings suggest that, at least in PPMS, cortical lesions accrual could share a common pathophysiological mechanism with periventricular NAWM abnormalities development but not with WM lesion formation or with deep NAWM alterations.

WM lesions nearly always form around veins and while some GM lesions also appear to do so, subpial cortical GM lesions (the most abundant type of GM lesion in progressive MS) do not follow the same pattern ([@bb0010]), and have instead been linked with overlying meningeal inflammation ([@bb0030]). The absence of a clear association between cortical and WM lesion loads could be due to the different roles played by veins in cortical and WM lesions formation and by the high density of veins in the periventricular region. This finding is in line with previous work on relapse-onset MS ([@bb0045]), where it was showed that NAWM alterations, but not WM lesion density, were consistently inversely proportional to the distance from the tissue/CSF boundary.

The pathological bases of gradients in periventricular NAWM abnormalities, observed in people with relapse-onset MS ([@bb0040], [@bb0045]) and with clinically isolated syndrome ([@bb0015]) is unknown, and speculation on possible mechanisms that may link NAWM abnormalities and cortical lesions is therefore difficult. From an anatomical point of view, proximity of cortical lesions and periventricular NAWM abnormalities to the surface of the brain raises the possibility of a common factor surrounding the brain being relevant. While meningeal inflammatory changes have been observed in MS, and linked with demyelination and neuronal loss in underlying cortical GM, ([@bb0010], [@bb0030]) ependymal abnormalities described as 'granular ependymitis' have only been seen in one study ([@bb0005]). Proximity to CSF could also offer a possible explanation for our findings, as there is in vitro evidence that CSF in MS is neurotoxic ([@bb0075]).

The lack of correlation between periventricular damage and cortical thickness, on the other hand, is not in line with a previous study on RRMS and CIS subjects, where an association between cortical thickness and periventricular lesions was observed ([@bb0035]). Compared to the RRMS/CIS subjects, however, our patients probably present with more marked structural alterations, together with a longer disease duration. Moreover our patient group was smaller when compared to the aforementioned RRMS/CIS study, even if probably less heterogeneous. Future studies are needed to shed more light on the possible differences in the association between cortical thickness and white matter lesions across the different disease subtypes.

To try to reduce partial volume effects from CSF and WM lesions, we excluded all WM voxels within 2 mm of the ventricles or WM lesions. However, as periventricular NAWM abnormalities are more marked close to the ventricles, it is likely that this will have reduced sensitivity to periventricular NAWM abnormalities and lead us to underestimate the strength of associations with cortical lesions. Moreover, to control for a possible confounding effect due to inter-subject differences in ventricular volume, we used a non-linear registration to a common space, included in the TBSS pipeline, and we verified that correcting for nBV did not significantly change the results.

Multiple correlations have been undertaken, and so it is possible that some of the associations found may be spurious, however the correlation between periventricular NAWM abnormalities and cortical lesion load would survive a Bonferroni correction, if applied, and all key results survive a FDR-correction for multiple comparisons. In addition, the moderate sample size counsels caution when seeking to generalise the present findings, which however, are consistent with recent observations in relapse onset MS.

In conclusion, our findings suggest that there is an association between cortical lesion load and periventricular NAWM abnormalities, and so potentially a shared factor contributes to these two facets of MS pathology in PPMS.
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